Silo Pharma Enters Exclusive License Agreement For SPC-15 Drug Candidate - Quick Facts

(RTTNews) - Silo Pharma (SILO) announced it has entered into an exclusive, global license agreement with Columbia University to further develop, manufacture, and commercialize its lead drug candidate, SPC-15, an intranasal treatment for stress-induced affective disorders and PTSD. The company said it is engaged in the final steps required before submission of an IND application to the FDA to begin first-in-human clinical studies.

"In our opinion, the execution of the exclusive license agreement for our SPC-15 product is a critical step for our company which we believe could increase shareholder value in the future, subject to FDA approval if and when received," said Silo CEO Eric Weisblum.

For More Such Health News, visit rttnews.com.